Catheter ablation for atrial fibrillation has enjoyed an uneven reputation at best over the years, but the prospect of eliminating anti-arrhythmic drugs has proven difficult for both patients and clinicians to ignore. A new analysis of data from the Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) study seems to answer the cost effectiveness question for ablation, however, representing yet another piece of evidence that should support increased sales of these devices in the coming years.